Gallium-68 Radiopharmaceuticals for Cardiac Perfusion Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current myocardial perfusion imaging agents for PET and SPECT imaging face challenges such as limited first-pass extraction, poor liver clearance, and high background noise, which affect image quality and sensitivity in cardiac studies.
Innovation Solution
Development of gallium(III) agents with an organic scaffold possessing six donor atoms, resulting in an octahedral geometry, which enhances myocardial uptake, reduces liver retention, and improves blood-brain barrier penetration, allowing for high target-to-background ratios and efficient clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional myocardial perfusion imaging agents (99mTc-Sestamibi, 201Tl) are used, then imaging is available, but first pass extraction is limited at high flow
Solution Approach 1:
The patent modifies the chemical parameters of the imaging agent by incorporating gallium(III) with a specific organic scaffold containing six donor atoms arranged in an octahedral geometry. This structural parameter change enables enhanced first pass extraction at high flow conditions while maintaining reliable image quality through improved myocardial uptake and retention characteristics
2Measurement precision
If conventional agents (99mTc-Sestamibi, 99mTc-teboroxime, 99mTc-Tetrofosmin, 99mTc-Q complexes) are used, then imaging is available, but liver clearance is poor
Solution Approach 1:
The patent changes the chemical composition parameter by using gallium(III) instead of technetium-99m, combined with a specific organic scaffold structure. This parameter change results in improved liver clearance and reduced background noise from adjacent tissues, thereby enhancing the signal-to-noise ratio for better image interpretation
3Measurement precision
If conventional agents are used, then imaging is available, but target-to-background ratio is reduced
Solution Approach 1:
The patent employs gallium(III) with a specific octahedral organic scaffold to change the pharmacokinetic parameters of the imaging agent. This results in enhanced myocardial retention and reduced background noise, achieving superior target-to-background ratios that improve image quality and clinical interpretability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gallium(III) agents demonstrate high myocardial uptake and retention, improved liver clearance, and enhanced brain penetration, leading to superior image quality and target-to-background ratios, suitable for cardiac perfusion imaging and neurodegenerative disease monitoring.
Implementation Method 1
The gallium(III) agents demonstrate high myocardial uptake and retention
Implementation Method 2
improved liver clearance
Implementation Method 3
enhanced brain penetration
Data Source
AI summary
Tracers that can be used for PET or SPECT imaging of the distribution of Pgp are disclosed. The tracers are metalloprobes that can comprise a radioactive metal ion such as 67Ga or 68Ga. Methods of synthesizing the tracers, and methods of imaging heart and other tissues are also disclosed. The tracers can be used to obtain high signal-to-background ratios for imaging tissues in vivo such as heart or tumor tissue. In various embodiments, disclosed tracers can exhibit, a) enhanced first pass extraction into heart tissue compared to presently available probes, b) linearity with true blood flow, c) enhanced detection of myocardial viability compared to presently available probes, d) reduced liver retention compared to presently available probes, and e) more efficient clearance from non-cardiac and adjoining tissues compared to presently available probes.